SEC Comment Letter for Sonoma Pharmaceuticals, Inc. (SNOA) (CIK 0001367083) (SNOA) — Oct 23, 2018
Sonoma Pharmaceuticals, Inc. (SNOA) (CIK 0001367083)
Date: Oct. 23, 2018 · CIK: 0001367083 · Accession: 0000000000-18-033206
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-227806
Letter
October 23, 2018 Jim Schutz Chief Executive Officer Sonoma Pharmaceuticals, Inc. 1129 N. McDowell Blvd. Petaluma, CA 94954 Re:Sonoma Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed October 12, 2018 File No. 333-227806 Dear Mr. Schutz: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Dorrie Yale at 202-551-8776 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance cc: Amy Trombly
Show Raw Text
October 23, 2018
Jim Schutz
Chief Executive Officer
Sonoma Pharmaceuticals, Inc.
1129 N. McDowell Blvd.
Petaluma, CA 94954
Re:Sonoma Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed October 12, 2018
File No. 333-227806
Dear Mr. Schutz:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Dorrie Yale at 202-551-8776 with any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Amy Trombly